# ImmuPharma PLC Last Lupuzor Patient Successfully Completed Dosing

- Link: https://www.directorstalkinterviews.com/immupharma-plc-last-lupuzor-patient-successfully-completed-dosing/412742615
- Published: 2017-12-21T09:48:50+00:00
- Author: Amilia Stone

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company,
has today confirmed that the last patient has completed dosing within the 52-week,
randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme
for the potential breakthrough compound for Lupus, the life threatening auto-immune
disease.

Study summary as at 21 December 2017

·     200 patients successfully recruited and randomised (dosed)

·     Last patient successfully completed dosing

·      Continued robust safety record which remains consistent with Lupuzor™’s product
profile as shown in its previous Phase IIb study

·      Top line results remain on track to be reported in Q1 2018

> **Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma said**:“
> We are delighted to announce this significant milestone that all patients have
> now completed dosing in this pivotal Phase III trial for Lupuzor™. Importantly
> we continue to see robust safety and we look forward with continued confidence
> to reporting top line results of the study in Q1 2018.”

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/
NCT02504645

Share on: